Redirecting immune signaling with cytokine adaptors

Gita C. Abhiraman, Karsten D. Householder, Grayson E. Rodriguez, Caleb R. Glassman, Robert A. Saxton, Cort B. Breuer, S. Wilson, Leon Su, Michelle Yen, Cynthia L. Hsu, Venu G. Pillarisetty, Nathan E. Reticker-Flynn, K. Christopher GarcíaNature Communications 2025 · DOI

TL;DR

Researchers have engineered "cytokine adaptors," soluble molecules that act as molecular switches to redirect immune signals. These adaptors can convert an immunosuppressive signal into a stimulatory one (or vice versa) by leveraging the presence of a disease-associated cytokine, offering a more targeted approach to immune modulation with potentially fewer side effects than current therapies.

What Problem Does This Paper Address?

Cytokines are crucial for coordinating immune responses, but their dysregulation is implicated in many diseases, including cancer and autoimmune disorders. While blocking problematic cytokines (cytokine blockade) is a common therapeutic strategy, directly activating immune-boosting pathways with cytokines (cytokine agonism) has been challenging. This is largely due to the pleiotropic effects of cytokines – meaning a single cytokine can act on many different cell types through widely expressed receptors, leading to unwanted side effects. For example, systemic IL-2 administration, while immune-stimulating, can cause severe toxicity like capillary leak syndrome. The challenge, therefore, is to achieve targeted cytokine agonism or to convert harmful signals into beneficial ones specifically at the site of disease, without causing widespread off-target effects.

Methods

The core innovation is the design of "cytokine adaptors." These are modular, soluble protein molecules engineered to act as molecular switches. The general principle involves:

  1. Targeting the input cytokine: The adaptor has binding domains that recognize and bind to a specific "input" cytokine (e.g., TGF-β, IL-10, IL-23, IL-17).
  2. Leveraging receptor dimerization: Cytokine signaling typically occurs when cytokine receptors dimerize (come together) on the cell surface. The adaptors are designed to bind to the input cytokine in a way that forces the dimerization of different cytokine receptors, thereby activating a new signaling pathway.
  3. Conditional activation: Crucially, these adaptors have no intrinsic signaling activity. They only become active when the specific input cytokine is present, acting as a scaffold to nucleate the adaptor-cytokine complex and trigger the desired downstream signaling.

The researchers engineered various adaptor constructs, including:

  • Two-component systems: Separate molecules that, when bound to the input cytokine, bring together the target receptors.
  • Single-component systems: A single molecule where the binding domains for the input cytokine and the target receptor are linked, allowing for more precise control over receptor proximity.

They used techniques like flow cytometry to measure intracellular signaling (e.g., pSTAT5, pSMAD2/3), ELISA to quantify cytokine production, and cell proliferation assays to assess functional outcomes in human immune cells (T cells, PBMCs, NK cells) and cell lines (YT-1, THP-1).

Datasets

Not discussed in the paper. The study primarily relies on in vitro experiments using established human cell lines and primary immune cells, as well as in vivo mouse models for some aspects.

Key Insights and Ideas

  • Cytokines as "scaffolds": The key conceptual breakthrough is using disease-associated cytokines, which are often present at elevated levels in pathological conditions, as local "scaffolds" to recruit and activate therapeutic adaptor molecules. This turns a negative signal into a positive one, or vice versa, only where it's needed.
  • Conditional, context-dependent agonists: Cytokine adaptors are designed to be inactive on their own. Their activity is strictly dependent on the presence of the target cytokine, making them "conditional" and "context-dependent" agonists. This is a major advantage over systemic cytokine administration.
  • Reversing immune suppression: The adaptors can convert immunosuppressive signals (like TGF-β or IL-10, often found in the tumor microenvironment) into immunostimulatory signals (like IL-2), potentially unleashing anti-tumor immunity.
  • Converting inflammation to suppression: Conversely, they can convert pro-inflammatory signals (like IL-23 or IL-17, implicated in autoimmune diseases) into immunosuppressive signals (like IL-10), offering a way to dampen harmful inflammation.
  • Modular design for broad applicability: The modular nature of the adaptors (linking different binding domains) suggests this approach could be adapted for many different cytokine pairs and potentially other receptor systems.

Key Results

  • TGF-β → IL-2 Adaptors: Engineered adaptors successfully converted TGF-β signals into IL-2 receptor signaling, leading to pSTAT5 activation in human T cells. This adaptor reversed TGF-β-induced T cell suppression and promoted T cell proliferation, IFN-γ, and TNF-α production.
  • IL-10 → IL-2 Adaptors: Similar adaptors were created to convert IL-10 signals into IL-2 receptor signaling, inducing pSTAT5 activation in human T cells.
  • IL-23 → IL-10 Adaptors: These adaptors successfully converted IL-23 signals into IL-10 receptor signaling, suppressing LPS-induced production of inflammatory cytokines (TNF-α, IL-6, IL-1β) in human PBMCs in an IL-23-dependent manner.
  • IL-17 → IL-10 Adaptors: Analogous adaptors converted IL-17 signals into IL-10 receptor signaling, also suppressing LPS-induced inflammatory cytokine production in human PBMCs, specifically in the presence of IL-17A.
  • Specificity: The signaling induced by the adaptors was dependent on the presence of the intended input cytokine, demonstrating the specificity of the system.

Limitations and Future Work

  • Human-specific: The current adaptors are engineered for human cytokines and receptors. Testing in animal models is necessary to assess in vivo efficacy and safety, as species cross-reactivity is limited.
  • In vivo validation: While in vitro results are promising, the in vivo activity and therapeutic window of these adaptors in disease models need to be thoroughly investigated. Dosing studies will be crucial to determine optimal concentrations and potential off-target effects in a complex biological system.
  • Broader applications: The authors suggest that this adaptor technology could be extended to other cytokine pairs and potentially to target other pathological markers, such as tumor antigens, to convert them into receptor agonists. Further exploration of different adaptor formats and binding modules is warranted.

Summary updated

Abstract

Cytokines are signaling molecules that coordinate complex immune processes and are frequently dysregulated in disease. While cytokine blockade has become a common therapeutic modality, cytokine agonism has had limited utility due to the widespread expression of cytokine receptors with pleiotropic effects. To overcome this limitation, we devise an approach to engineer molecular switches, termed cytokine adaptors, that transform one cytokine signal into an alternative signal with a different functional output. Endogenous cytokines act to nucleate the adaptors, converting the cytokine-adaptor complex into a surrogate agonist for a different cytokine pathway. In this way, cytokine adaptors, which have no intrinsic agonist activity, can function as conditional, context-dependent agonists. We develop cytokine adaptors that convert IL-10 or TGF-β into IL-2 receptor agonists to reverse T cell suppression. We also convert the pro-inflammatory cytokines IL-23 or IL-17 into immunosuppressive IL-10 receptor agonists. Thus, we show that cytokine adaptors can convert immunosuppressive cytokines into immunostimulatory cytokines, or vice versa. Unlike other methods of immune conversion that require cell engineering, cytokine adaptors are soluble molecules that leverage endogenous cues from the microenvironment to drive context-specific signaling.
BibTeX
@inproceedings{abhiraman2025redirecting,
  author = {Gita C. Abhiraman and Karsten D. Householder and Grayson E. Rodriguez and Caleb R. Glassman and Robert A. Saxton and Cort B. Breuer and S. Wilson and Leon Su and Michelle Yen and Cynthia L. Hsu and Venu G. Pillarisetty and Nathan E. Reticker-Flynn and K. Christopher García},
  title = {{Redirecting immune signaling with cytokine adaptors}},
  booktitle = {Nature Communications},
  year = {2025},
  doi = {10.1038/s41467-025-57681-1},
}
Figure